Affymax, a biopharmaceutical company, has announced positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients.

The U.S. Food and Drug Administration issued an advisory about preliminary results of a German study involving the drug known as Procrit, Eprex or Epogen.

BRIDGEWATER, N.J., Sept. 17 /PRNewswire/ -- Ortho Biotech has become aware of preliminary data from an investigator-initiated experimental study of the effects of Epoetin alfa in patients with acute ischemic stroke.

Takeda Pharmaceutical Company Limited (TOKYO:4502) and Affymax, Inc.

Affymax, Inc. (Nasdaq:AFFY) today announced that Affymax management will host a conference call and webcast at 5:00 p.m. Eastern Time today.